
zzso zzso scanning of zzso dominant zzso carriers for Alzheimer's disease provides an opportunity to track changes that could zzso symptoms or clinical diagnosis of the zzso We used zzso zzso to assess how zzso and zzso volumes change as familial Alzheimer's disease zzso from the zzso stage through to zzso 

Nine zzso carriers had serial clinical assessments and zzso zzso scans (41 zzso range zzso per zzso at different clinical stages zzso mild cognitive zzso or clinical Alzheimer's zzso 25 healthy controls had serial scanning (54 zzso range 2-4 per zzso for zzso We measured whole brain and total zzso volumes using zzso techniques, and adjusted for total zzso zzso zzso models were developed to estimate differences in volume and zzso rate between zzso carriers and controls in relation to when the disease was clinically zzso 

zzso carriers had significantly increased zzso and zzso zzso rates compared with controls and these differences increased with zzso zzso in zzso and zzso zzso rates between controls and zzso carriers were evident zzso and zzso years, respectively, before diagnosis of Alzheimer's zzso At a zzso level, differences in mean zzso volume between zzso carriers and controls became significant 3 years before clinical diagnosis, whereas differences in mean brain volumes became significant only 1 year before zzso 

zzso changes can be seen on zzso scans that zzso the clinical onset of familial Alzheimer's zzso zzso measures of zzso rates can identify differences between zzso carriers and controls 2-3 years earlier than zzso zzso zzso 

